We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Abbvie Inc (ABBV) Ordinary Shares USD 0.01

Sell:$171.71 Buy:$171.72 Change: $4.20 (2.50%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$171.71
Buy:$171.72
Change: $4.20 (2.50%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$171.71
Buy:$171.72
Change: $4.20 (2.50%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.

Contact details

Address:
1 N Waukegan Rd
NORTH CHICAGO
60064
United States
Telephone:
+1 (847) 9327900
Website:
https://www.abbvie.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ABBV
ISIN:
US00287Y1091
Market cap:
$294.35 billion
Shares in issue:
1.77 billion
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Richard Gonzalez
    Executive Chairman of the Board
  • Robert Michael
    Chief Executive Officer, Director
  • Scott Reents
    Chief Financial Officer, Executive Vice President
  • Timothy Richmond
    Chief Human Resource Officer, Executive Vice President
  • Roopal Thakkar
    Executive Vice President - Research & Development, Chief Scientific Officer
  • Perry Siatis
    Executive Vice President, General Counsel, Company Secretary
  • Nicholas Donoghoe
    Executive Vice President, Chief Business and Strategy Officer
  • Azita Saleki-Gerhardt
    Executive Vice President, Chief Operations Officer
  • Jeffrey Stewart
    Executive Vice President, Chief Commercial Officer
  • Kevin Buckbee
    Senior Vice President, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.